Stockscreener 앱 받기
0.18
5.88%
0.010
시간 외 거래:
.18
전일 마감가:
$0.17
열려 있는:
$0.1655
하루 거래량:
2.00M
Relative Volume:
1.23
시가총액:
$11.78M
수익:
$1.56M
순이익/손실:
$-62.68M
주가수익비율:
-0.1154
EPS:
-1.56
순현금흐름:
$-64.35M
1주 성능:
-1.42%
1개월 성능:
+1.12%
6개월 성능:
-31.19%
1년 성능:
-95.96%
1일 변동 폭
$0.1655
$0.1851
1주일 범위
$0.1655
$0.1924
52주 변동 폭
$0.1625
$6.79
Lyra Therapeutics Inc Stock (LYRA) Company Profile
명칭
Lyra Therapeutics Inc
전화
617-373-4600
주소
480 ARSENAL WAY, WATERTOWN, MA
LYRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.18 | 11.78M | 1.56M | -62.68M | -64.35M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-05-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-05-06 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | 재개 | BTIG Research | Buy |
| 2023-08-31 | 개시 | H.C. Wainwright | Buy |
| 2022-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-26 | 개시 | BTIG Research | Buy |
| 2020-05-26 | 개시 | BofA/Merrill | Buy |
| 2020-05-26 | 개시 | Jefferies | Buy |
| 2020-05-26 | 개시 | William Blair | Outperform |
모두보기
Lyra Therapeutics Inc 주식(LYRA)의 최신 뉴스
Lyra Therapeutics reshuffles board, adjusts director classes - Investing.com
Lyra Therapeutics reshuffles board, adjusts director classes By Investing.com - Investing.com UK
Lyra Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lyra Therapeutics Inc’s (NASDAQ: LYRA) Stock Forecast: Increase To $0.5 In A Year - Stocks Register
Chronic Rhinosinusitis Without Nasal Polyps Therapeutics Market Size was ~USD 3,930 Million in the 7MM in 2023, estimated DelveInsight - Barchart
Incendia Therapeutics Names Healthcare Veteran Brad Smith as CFO, Brings $1B Financing Track Record - StockTitan
LYRA (Lyra Therapeutics) GF Score : 43/100 (As of Nov. 29, 2024) - GuruFocus.com
Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Price Target at $4.50 - Defense World
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital
William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Lyra Therapeutics Inc (LYRA) Q3 2024 Earnings: Net Loss of $11.9M, Misses EPS and Revenue Estimates - GuruFocus.com
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Lyra Therapeutics Reports Strong Safety Data, Cuts Q3 Losses by 24% as LYR-210 Advances | LYRA Stock News - StockTitan
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $4.50 - Defense World
Chronic Rhinosinusitis Market: Driving Rapid Growth with Top - openPR
Lyra Therapeutics Inc (NASDAQ: LYRA) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Lyra Therapeutics completes Phase 3 trial enrollment for CRS treatment By Investing.com - Investing.com Canada
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - The Manila Times
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Market Momentum: Lyra Therapeutics Inc (LYRA) Registers a 3.08 Increase, Closing at 0.24 - The Dwinnex
Lyra Therapeutics Inc (LYRA)’s stock price in review: A technical analysis - US Post News
Lyra Therapeutics Inc: Navigating a Turbulent Year, Up -96.61% from 52-Week Low - The InvestChronicle
Lyra Therapeutics stock plunges to 52-week low of $0.24 - Investing.com
Lyra Therapeutics stock plunges to 52-week low of $0.24 By Investing.com - Investing.com UK
What is the investor’s view on Lyra Therapeutics Inc (LYRA)? - US Post News
The time has not yet come to remove your chips from the table: Lyra Therapeutics Inc (LYRA) - SETE News
Where Do Analysts Think The Lyra Therapeutics Inc (NASDAQ: LYRA) Is Going - Stocks Register
Lyra Therapeutics Inc (LYRA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Lyra Therapeutics to Present Study Results for LYR-210 and - GlobeNewswire
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - StockTitan
Lyra Therapeutics stock plunges to 52-week low of $0.25 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.25 - Investing.com
Market Recap: Lyell Immunopharma Inc (LYEL)’s Positive Momentum, Closing at 1.46 - The Dwinnex
XTX Topco Ltd Invests $500,000 in Lindsay Co. (NYSE:LNN) - MarketBeat
Great Point Partners LLC Purchases New Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Understanding LXRX’s book value per share for better investment insights - US Post News
All You Need to Know About Tyler Technologies (TYL) Rating Upgrade to Buy - Yahoo Finance
Upward Trajectory: Lexicon Pharmaceuticals Inc (LXRX) Posts a Slidee, Closing at 1.58 - The Dwinnex
Lyell Immunopharma Inc (LYEL)’s stock price in review: A technical analysis - US Post News
Intech Investment Management LLC Buys 1,502 Shares of Tyler Technologies, Inc. (NYSE:TYL) - MarketBeat
Citigroup Acquires Substantial Stake in Syrah Resources - TipRanks
Analysts review Tyler Technologies, Inc.’s rating - Knox Daily
Ratio Examination: Lyra Therapeutics Inc (LYRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Tyler Technologies, Inc. (NYSE:TYL) Receives $582.31 Average Target Price from Analysts - MarketBeat
GILD: 3 Biotech Stocks to Watch as FDA Approvals Roll In - StockNews.com
Lyra Therapeutics Inc (LYRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):